Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$0.61 USD

0.61
604,160

-0.01 (-1.06%)

Updated Aug 28, 2024 04:00 PM ET

After-Market: $0.61 0.00 (-0.72%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Amarin Corporation PLC [AMRN]

Reports for Purchase

Showing records 221 - 240 ( 365 total )

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 221

03/01/2018

Company Report

Pages: 5

2018 Ought to Mark End of a Long Journey (or a New Beginning); Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 222

11/02/2017

Company Report

Pages: 6

3Q Update: Getting Our Ducks in a Row Ahead of REDUCE-IT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 223

08/03/2017

Company Report

Pages: 5

We Believe There Is Now an Attractive Entry Point Heading Into Interim Readout

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 224

06/27/2017

Daily Note

Pages: 4

CANTOS Study Further Validates Mechanism and Commercial Upside to REDUCE-IT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 225

06/01/2017

Daily Note

Pages: 6

Historical Rx Review Suggests Limited Downside to Vascepa Underlying Revenue From Potential REDUCE-IT Miss

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 226

05/05/2017

Company Report

Pages: 6

1Q Update: Events Tracking to Expectation, Focus Remains on REDUCE-IT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 227

03/01/2017

Company Report

Pages: 5

Continued Uptick in Vascepa Scripts to Support a Cash Flow Positive 2017

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 228

01/23/2017

Company Report

Pages: 6

REDUCE-IT Topline Now Within Sight

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 229

08/05/2016

Company Report

Pages: 8

Amarin?s Strategic Alpha Trade-Off

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 230

07/12/2016

Daily Note

Pages: 4

Is REDUCE-IT a Free Lunch?

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 231

05/06/2016

Company Report

Pages: 7

REDUCE-IT Stays on the Right Side of the Track: 1Q16 Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 232

02/26/2016

Company Report

Pages: 7

Thinking Through The Upcoming Interim Look

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 233

11/05/2015

Company Report

Pages: 8

Promotion of ANCHOR May Give Early Peek at Market for REDUCE-IT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 234

08/10/2015

Company Report

Pages: 8

How Much Is Off-label Promotion into a 10x Market Worth?

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 235

05/11/2015

Company Report

Pages: 8

Amarin Spars On With Its Best Fist Forward

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 236

03/12/2015

Company Report

Pages: 14

REDUCE-IT Revisited: Upgrading to a Buy Rating and raising PT to $10

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 50.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 237

04/16/2014

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: MARTIN J

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 238

04/01/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 239

04/01/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 240

04/01/2014

Company Report

Pages: 7

Finds A Friend in Kowa

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party
// eof